| abstract |
These compounds are fatty acid synthase inhibitors and can be used, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation. Claim 1: Compounds of the formula (1) wherein: R denotes Ar, Het, -C ° C-Ar or -C ° C-Het; W denotes NR²R² or Het¹; R¹ denotes A, [C (R³) ₂] ₙAr¹ or [C (R³) ₂] ₙCyc; R², R² each denote, independently of each other, H, A or [C (R³) ₂] ₙCyc; R⁴ denotes H, F, Cl, Br, OH, CN, NO₂, A, OA, SA, SO₂Me, COA, CONH₂, CONHA or CONA₂; X¹, X², X³, X⁴ each denote, independently of each other, CH or N; A denotes unbranched or branched alkyl 1-10 C atoms, where two adjacent carbon atoms can form a double bond and / or one or two non-adjacent CH and / or CH₂ groups can be replaced by atoms of N, O and / or S and wherein 1-7 atoms of H may be replaced by R⁵; Cyc denotes cycloalkyl with 3-7 C atoms, which is not substituted or which is monosubstituted with OH, Hal or A; A denotes unbranched or branched alkyl 1-6 atoms of C, wherein 1-5 atoms of H may be replaced by F; R⁵ denotes F, Cl or OH; Ar denotes phenyl, which is unsubstituted or which is mono-, di-, tri-, tetra- or pentas substituted with Hal, A, O [C (R³) ₂] ₙHet¹, Ar¹, [C (R³) ₂] OR³, [C (R³) ₂] ₚN (R³) ₂, NO₂, CN, [C (R³) ₂] ₚCOOR³, WITH (R³) ₂, [C (R³) ₂] ₚN (R³) ₂, N (R³) ₂COA , NR³SO₂A, [C (R³) ₂] ₚSO₂N (R³) ₂, S (O) ₙA, O [C (R³) ₂] ₘN (R³) ₂, NHCOOA, NHCON (R³) ₂ and / or COA; Ar¹ denotes phenyl or naphthyl, which is not substituted or which is mono-, di-, tri-, tetra- or pentas substituted with Hal, A, [C (R³) ₂] ₚOR³, [C (R³) ₂] N (R³ ) ₂, NO₂, CN, [C (R³) ₂] ₚCOOR³, [C (R³) ₂] ₚN (R³) ₂, N (R³) ₂COA, NR³SO₂A, [C (R³) ₂] ₚSO₂N (R³) ₂, S (O) ₙA, O [C (R³) ₂] ₘN (R³) ₂, NHCOOA, NHCON (R³) ₂ and / or COA; R³ denotes H or unbranched or branched alkyl 1-6 C atoms; Het denotes a saturated, unsaturated or aromatic mono- or bicyclic heterocycle having 1 to 4 atoms of N, O and / or S, which is not substituted or which is mono-, di-, tri-, tetra- or pentas substituted with Hal , A, [C (R³) ₂] ₙOA, [C (R³) ₂] ₙN (R³) ₂, SR³, NO₂, CN, COOR³, CON (R³) ₂, COHet¹, NR³COA, NR³SO₂A, SO₂N (R³) ₂ , S (O) ₙA, O [C (R³) ₂] ₘN (R³) ₂, NHCOOA, NHCON (R³) ₂, CHO, COA, = S, = NH, = NA and / u = O (carbonyl oxygen ); Het¹ denotes a saturated, unsaturated or aromatic mono- or bicyclic heterocycle having 1 to 4 atoms of N, O and / or S, which is not substituted or which is mono-, di-, tri-, tetra- or pentas substituted with Hal , A, [C (R³) ₂] ₙOR³, [C (R³) ₂] ₙN (R³) ₂, SR³, NO₂, CN, COOR³, CON (R³) ₂, NR³COA, NR³SO₂A, SO₂N (R³) ₂, S (O) ₙA, O [C (R³) ₂] ₘN (R³) ₂, NHCOOA, NHCON (R³) ₂, CHO, COA, = S, = NH, = NA and / or = O (carbonyl oxygen); Hal denotes F, Cl, Br or I; m denotes 1, 2 or 3; n denotes 0, 1 or 2; p denotes 0, 1, 2, 3 or 4; provided that only one or two of X¹, X², X³, X⁴ denote N; and its pharmaceutically acceptable salts, tautomers and stereoisomers, including mixtures in all proportions. |